NO984197L - FremgangsmÕte for behandling av autisme - Google Patents

FremgangsmÕte for behandling av autisme

Info

Publication number
NO984197L
NO984197L NO984197A NO984197A NO984197L NO 984197 L NO984197 L NO 984197L NO 984197 A NO984197 A NO 984197A NO 984197 A NO984197 A NO 984197A NO 984197 L NO984197 L NO 984197L
Authority
NO
Norway
Prior art keywords
procedure
treating autism
treating
autism
olanzapine
Prior art date
Application number
NO984197A
Other languages
English (en)
Norwegian (no)
Other versions
NO984197D0 (no
Inventor
Jr Charles M Beasley
Gary D Tollefson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO984197D0 publication Critical patent/NO984197D0/no
Publication of NO984197L publication Critical patent/NO984197L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Luminescent Compositions (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Transplanting Machines (AREA)
NO984197A 1996-03-11 1998-09-11 FremgangsmÕte for behandling av autisme NO984197L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1316296P 1996-03-11 1996-03-11
PCT/US1996/019576 WO1997033585A1 (en) 1996-03-11 1996-12-04 Method for treating autism

Publications (2)

Publication Number Publication Date
NO984197D0 NO984197D0 (no) 1998-09-11
NO984197L true NO984197L (no) 1998-11-03

Family

ID=21758619

Family Applications (1)

Application Number Title Priority Date Filing Date
NO984197A NO984197L (no) 1996-03-11 1998-09-11 FremgangsmÕte for behandling av autisme

Country Status (19)

Country Link
EP (1) EP0946179B1 (de)
JP (1) JP2000506860A (de)
KR (1) KR19990087715A (de)
CN (1) CN1213970A (de)
AT (1) ATE249832T1 (de)
AU (1) AU709181B2 (de)
BR (1) BR9612552A (de)
CA (1) CA2248741A1 (de)
CZ (1) CZ290498A3 (de)
DE (1) DE69630055T2 (de)
EA (1) EA000768B1 (de)
ES (1) ES2206614T3 (de)
HU (1) HUP9903688A3 (de)
IL (1) IL126161A0 (de)
NO (1) NO984197L (de)
NZ (1) NZ324615A (de)
PL (1) PL328948A1 (de)
TR (1) TR199801798T2 (de)
WO (1) WO1997033585A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1133299A1 (de) 1998-11-23 2001-09-19 Sepracor Inc. 2-hydroxymethylolanzapine enthaltende zusammensetzungen und verfahren
CA2351718A1 (en) 1998-11-23 2000-06-02 Sepracor Inc. Desmethylolanzapine compositions and methods
JP2002530340A (ja) * 1998-11-23 2002-09-17 セプラコール， インク． オランザピン−ｎ−オキサイドを含む医薬組成物
CA2879113C (en) 2012-07-22 2021-11-16 Indiana University Research And Technology Corporation Modulation sapp, sapp alpha and bdnf levels in individuals diagnosed with fxs and asd
RU2696481C2 (ru) 2013-10-14 2019-08-02 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Применение акампросата для модулирования активации erk1/2 в животных моделях fxs и asd и людей с диагностированными fxs и asd
RU2666598C1 (ru) * 2017-07-14 2018-09-11 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Средство для коррекции расстройств аутистического спектра
KR102285577B1 (ko) 2020-11-11 2021-08-04 김의철 자폐를 가진 유소년의 무약물 치료방법 및 시스템

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use

Also Published As

Publication number Publication date
EP0946179A1 (de) 1999-10-06
JP2000506860A (ja) 2000-06-06
HUP9903688A3 (en) 2001-12-28
KR19990087715A (ko) 1999-12-27
EA199800821A1 (ru) 1999-02-25
BR9612552A (pt) 1999-07-20
AU1150197A (en) 1997-10-01
CN1213970A (zh) 1999-04-14
HUP9903688A2 (hu) 2000-03-28
ATE249832T1 (de) 2003-10-15
CZ290498A3 (cs) 1999-10-13
EP0946179B1 (de) 2003-09-17
AU709181B2 (en) 1999-08-26
DE69630055D1 (de) 2003-10-23
WO1997033585A1 (en) 1997-09-18
EP0946179A4 (de) 2000-04-19
NZ324615A (en) 2000-08-25
DE69630055T2 (de) 2004-06-03
CA2248741A1 (en) 1997-09-18
IL126161A0 (en) 1999-05-09
PL328948A1 (en) 1999-03-01
TR199801798T2 (xx) 1998-12-21
EA000768B1 (ru) 2000-04-24
ES2206614T3 (es) 2004-05-16
NO984197D0 (no) 1998-09-11

Similar Documents

Publication Publication Date Title
DE69829112D1 (de) Butyrate derivaten zur behandlung von fibromyalgia und chronische müdigkeit-syndrom
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
NO990279L (no) Isobutylgaba og dets derivater for behandling av smerte
NO971192L (no) Fremgangsmåter for avlevering av materialer inn i huden, og sammensetninger som blir anvendt
PT784476E (pt) Tratamento da esclerose multipla (em) e outras condicoes desmielinizantes utilizando lofepramina em combinacao com l-fenilalanina tirosina ou triptofano e opcionalmente um composto da vitamina b 12
DK0723444T3 (da) Levobupivacain, som er egnet til behandling af kronisk smerte
ATE181422T1 (de) Verfahren zur diagnose von praeklampsie
NO970533D0 (no) Blodbehandlingssystem og fremgangsmåte som overvåker citratretur til giveren
EE9700302A (et) Meetod maania ja bipolaarse häire raviks
NO984197L (no) FremgangsmÕte for behandling av autisme
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
NO984446L (no) FremgangsmÕte for behandling av smerte
NO20010390L (no) Behandling av angstsykdommer
NO984189L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
NO984196D0 (no) Fremgangsmåte for behandling av stoffmisbruk
BR9808866A (pt) Moléculas retinóicas relacionadas à inibição da superprodução de endotelina-1 em doenças
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
NO984190L (no) FremgangsmÕte for behandling av insomnia
NO984198L (no) FremgangsmÕte for behandling av aggresjon
RU94033502A (ru) Способ лечения детей, больных вторичным панкреатитом
UA7951A (uk) Спосіб сочетаної вакуум-лазерної терапії
MD950121A (ro) Metodă de tratare a urmărilor ictusurilor ischemice
NO984964L (no) Anvendelse av fosfonsyreestere for behandling av funksjonelle forstyrrelser i hjernen og ved depresjon
UA32384A (uk) Спосіб лікування пародонтиту
UA10743A (uk) Спосіб лікуваhhя хроhічhої лімфовеhозhої hедостатhості hижhіх кіhцівок

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application